- Report
- April 2025
- 200 Pages
Global
From €3934EUR$4,490USD£3,395GBP
- Report
- January 2026
- 193 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Report
- January 2026
- 196 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Report
- January 2026
- 181 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Report
- August 2025
- 186 Pages
Global
From €3451EUR$3,939USD£2,978GBP
- Report
- September 2025
- 250 Pages
Global
From €3934EUR$4,490USD£3,395GBP
- Report
- September 2025
- 250 Pages
Global
From €3934EUR$4,490USD£3,395GBP
- Report
- September 2025
- 250 Pages
Global
From €3934EUR$4,490USD£3,395GBP
- Report
- September 2025
- 250 Pages
Global
From €3934EUR$4,490USD£3,395GBP
- Report
- March 2024
- 159 Pages
Global
From €6965EUR$7,950USD£6,011GBP
- Report
- May 2024
- 138 Pages
Global
From €3504EUR$3,999USD£3,023GBP
- Report
- February 2026
- 50 Pages
Global
From €2322EUR$2,650USD£2,004GBP
Atenolol is a beta-blocker drug used to treat cardiovascular diseases such as hypertension, angina, and arrhythmias. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, that affect the heart and blood vessels. Atenolol is usually taken once or twice daily, with or without food. It is available in tablet, capsule, and liquid form.
Atenolol is a widely used drug in the cardiovascular market, as it is effective in treating a variety of conditions. It is also relatively inexpensive compared to other drugs in the same class. Additionally, it has a low risk of side effects, making it a popular choice for many patients.
In the Atenolol market, some of the major players include Pfizer, Novartis, Merck, and GlaxoSmithKline. Other companies such as Mylan, Teva, and Sandoz also produce generic versions of the drug. Show Less Read more